| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.069 | 0.02 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.02 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.02 |